哌拉西林/他唑巴坦治疗30例自发性腹膜炎的临床观察

The Treatment of 30 patients with Spontaneous Bacterial Peritonitis by Piperacillin/Tazobactam

目的观察哌拉西林/他唑巴坦(PIP/TAZ)治疗肝硬化合并自发性腹膜炎(SBP)的临床疗效和安全性。方法30例患者在护肝、利尿、支持、对症治疗的基础上给予哌拉西林/他唑巴坦4.5g,q8h,静脉滴注;主要观察治疗前后患者的临床症状、体征、腹水常规以及药物的不良反应等。结果用哌拉西林/他唑巴坦治疗肝硬化合并自发性腹膜炎的患者,总有效率可达83.33%,不良反应发生率6.67%。结论表明哌拉西林/他唑巴坦可以有效地控制自发性腹膜炎患者的细菌感染,可以作为经验性治疗SBP的首选药物。

Objective To evaluate the efficiency and safety of piperacillin/tazobactam in the treatment of cirrhotic patients with spontaneous bacterial peritonitis. Methods Thirty patients were given piperacillin/tazobactam at 4.5 g q8h in addition to the basis of comprehensive treatment consisting of protecting liver, diuresis, and related support. Clinical symptom, physical signs, alteration of ascites and adverse reaction etc. were observed and compared with pre-treatment. Results Clinical total effective rate was up to 83.33%.when conducting piperacillin/tazobactam in the treatment of cirrhotic patients with spontaneous bacterial peritonitis, while the occurring rate of adverse reaction merely was 6.67%. Conclusion Piperacillin/tazobactam is effective and safe in the treatment of cirrhotic patients with spontaneous bacterial peritonitis.